Strategic report Governance & remuneration Financial statements Investor information Notes to the financial statements continued 23 Inventories 2015 2014 m m Raw materials and consumables 1,563 1,156 Work in progress 1,453 1,604 Finished goods 1,700 1,471 4,716 4,231 24 Trade and other receivables 2015 2014 m m Trade receivables, net of provision for bad and doubtful debts 3,824 3,556 Accrued income 55 37 Other prepayments 307 252 Interest receivable 9 9 Employee loans and advances 36 28 Other receivables 1,384 718 5,615 4,600 Trade receivables included 8 million 2014 28 million due from associates and joint ventures.
Other receivables included nil 2014 8 million due from associates and joint ventures.
The increase in other receivables primarily arises from the Novartis transaction.
2015 2014 Bad and doubtful debt provision m m At 1 January 142 137 Exchange adjustments 2 3 Charge for the year 45 22 Subsequent recoveries of amounts provided for 17 13 Utilised 1 1 At 31 December 167 142 25 Cash and cash equivalents 2015 2014 m m Cash at bank and in hand 1,114 1,313 Short-term deposits 4,716 3,025 5,830 4,338 26 Assets held for sale 2015 2014 m m Property, plant and equipment 32 60 Goodwill 511 Other intangibles 5 543 Inventory 15 42 Other 6 46 1,156 Non-current assets and disposal groups are transferred to assets held for sale when it is expected that their carrying amounts will be recovered principally through disposal and a sale is considered highly probable.
They are held at the lower of carrying amount and fair value less costs to sell.
Included within Assets held for sale are assets which were written down to fair value less costs to sell of 36 million 2014 26 million.
The valuation methodology uses significant inputs which are not based on observable market data, therefore, this valuation is classied as level 3 in the fair value hierarchy.
